The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia
Open accessAbstract
OBJECTIVE: Deficits in working memory and cognitive control in schizophrenia are associated with impairments in prefrontal cortical function, including altered gamma band oscillations. These abnormalities are thought to reflect a deficiency in the synchronization of pyramidal cell activity that is dependent, in part, on gamma-aminobutyric acid (GABA) neurotransmission through GABA type A (GABA(A)) receptors containing alpha(2) subunits. The authors conducted a proof-of-concept clinical trial designed to test the hypothesis that a novel compound with relatively selective agonist activity at GABA(A) receptors containing alpha(2) subunits would improve cognitive function and gamma band oscillations in individuals with schizophrenia. METHOD: Participants were male subjects (N=15) with chronic schizophrenia who were randomly assigned to receive 4 weeks of treatment with the study drug MK-0777, a benzodiazepine-like agent with selective activity at GABA(A) receptors containing alpha(2) or alpha(3) subunits, or a matched placebo in a double-blind fashion. Outcome measures were the Brief Psychiatric Rating Scale (BPRS), Repeatable Battery for the Assessment of Neuropsychological Status, three tests of working memory and/or cognitive control (N-back, AX Continuous Performance Test, and Preparing to Overcome Prepotency), and EEG measures of gamma band oscillations induced during the Preparing to Overcome Prepotency task. RESULTS: Compared with placebo, the MK-0777 compound was associated with improved performance on the N-back, AX Continuous Performance Test, and Preparing to Overcome Prepotency tasks. The compound was also associated with increased frontal gamma band power during the Preparing to Overcome Prepotency task. No effects of the MK-0777 compound were detected in BPRS or Repeatable Battery for the Assessment of Neuropsychological Status scores, with the exception of improvement on the Repeatable Battery for the Assessment of Neuropsychological Status delayed memory index. The MK-0777 agent was well-tolerated. CONCLUSIONS: These findings provide preliminary support for the hypothesis that enhanced GABA activity at alpha(2) subunit containing GABA(A) receptors improves behavioral and electrophysiological measures of prefrontal function in individuals with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Self-citationTemporal dynamics of brain activation during a working memory task
Cohen, J. D., Perlstein, W. M., Braver, T. S., Nystrom, L. E., Noll, D. C., Jonides, J., & Smith, E. E. (1997) · Nature · doi:10.1038/386604a0 · Cited by 1,876
Guidotti, A., Auta, J., Davis, J. M., Gerevini, V. D., Dwivedi, Y., Grayson, D. R., Impagnatiello, F., Pandey, G., Pesold, C., Sharma, R., et al. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.11.1061 · Cited by 1,206
Compte, A. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.9.910 · Cited by 1,143
Gamma rhythms and beta rhythms have different synchronization properties
Kopell, N., Ermentrout, G. B., Whittington, M. A., & Traub, R. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1867 · Cited by 1,072 · cited 1×
“The precise mechanisms by which gamma oscillations support perception and cognition have been the subject of much theorizing, but both empirical (38,39) and theoretical (40,41) evidence suggest that synchronous oscillations serve as a mechanism by which cortical circuits can coordinate activity to support cognitive fu…”
BackgroundAkbarian, S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160008002 · Cited by 1,002
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Hashimoto, T., Volk, D. W., Eggan, S. M., Mirnics, K., Pierri, J. N., Sun, Z., Sampson, A. R., & Lewis, D. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06315.2003 · Cited by 938
Self-citation
Cited by
Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia
Lewis, D. A., Curley, A. A., Glausier, J. R., & Volk, D. W. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.10.004 · Cited by 1,071
Self-citationCognition in schizophrenia: core psychological and neural mechanisms
Barch, D. M., & Ceaser, A. (2012) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.015 · Cited by 747
Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes
Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733
“Some cognitive functions were improved with TPA023 treatmen”
BackgroundFerguson, B. R., & Gao, W.-J. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00037 · Cited by 594
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M. J., & Carter, C. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 506
Self-citationAlterations in Cortical Network Oscillations and Parvalbumin Neurons in Schizophrenia
Gonzalez-Burgos, G., Cho, R. Y., & Lewis, D. A. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.010 · Cited by 497
Self-citationLui, S., Li, T., Deng, W., Jiang, L., Wu, Q., Tang, H., Yue, Q., Huang, X., Chan, R. C., Collier, D. A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.84 · Cited by 365
Cho, K. K. A., Hoch, R., Lee, A. T., Patel, T., Rubenstein, J. L. R., & Sohal, V. S. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.019 · Cited by 329
Rudolph, U., & Möhler, H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135947 · Cited by 319
Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons
Wen, L., Lu, Y.-S., Zhu, X.-H., Li, X.-M., Woo, R.-S., Chen, Y.-J., Yin, D.-M., Lai, C., Terry, A. V., Vazdarjanova, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910302107 · Cited by 303
Mao, X. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1519 · Cited by 296
Gandal, M. J., Edgar, J. C., Klook, K., & Siegel, S. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.007 · Cited by 269
Alterations in cortical interneurons and cognitive function in schizophrenia
Dienel, S. J., & Lewis, D. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.06.020 · Cited by 272
Self-citationThe Dynamics of DNA Methylation in Schizophrenia and Related Psychiatric Disorders
Grayson, D. R., & Guidotti, A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.125 · Cited by 267
Alterations of cortical GABA neurons and network oscillations in schizophrenia
Gonzalez-Burgos, G., Hashimoto, T., & Lewis, D. A. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0124-8 · Cited by 260
Tests of unconditioned anxiety — Pitfalls and disappointments
Ennaceur, A. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.05.032 · Cited by 259
Treating Working Memory Deficits in Schizophrenia: A Review of the Neurobiology
Lett, T. A., Voineskos, A. N., Kennedy, J. L., Levine, B., & Daskalakis, Z. J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.026 · Cited by 257
Minzenberg, M. J., Firl, A. J., Yoon, J. H., Gomes, G. C., Reinking, C., & Carter, C. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.150 · Cited by 247
Self-citationSmucny, J., Dienel, S. J., Lewis, D. A., & Carter, C. S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01089-0 · Cited by 231
Self-citationGandal, M. J., Sisti, J., Klook, K., Ortinski, P. I., Leitman, V, Liang, Y., Thieu, T., Anderson, R., Pierce, R. C., Jonak, G., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.69 · Cited by 204
“To assess drug specificity, we also screened the antipsychotic risperidone and L-838,417, a subunit-selective GABAA-receptor a-2,3,5 (a-1 sparing) agonist similar to MK-0777, which was investigated on comparable measures in recent schizophrenia clinical trials.(54,60) L-838,417 represents a new class of benzodiazepine…”
MethodDeidda, G., Bozarth, I. F., & Cancedda, L. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00119 · Cited by 192
Vinkers, C. H., & Olivier, B. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/416864 · Cited by 195
“Indeed, increasing knowledge on the specific functions of different GABAA receptor subunits has led to a breakthrough of novel and more selective drugs acting at the benzodiazepine site of the GABAA receptor.”
BackgroundGlutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
“…et al. 1998), glycine B receptor agonists (Goff et al. 1995; Tsai and Lin 2010), mGluR5 agonists (Conn et al. 2009), drugs that enhance GABAA receptor function (Lewis et al. 2008), or drugs that attenuate glutamate release such as mGluR2/3 agonists or positive modulators (Patil et al. 2007).”
BackgroundBuchanan, R. W., Keefe, R. S. E., Lieberman, J. A., Barch, D. M., Csernansky, J. G., Goff, D. C., Gold, J. M., Green, M. F., Jarskog, L. F., Javitt, D. C., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.052 · Cited by 172
Cognitive impairments in psychotic disorders: common mechanisms and measurement
Barch, D. M., & Sheffield, J. M. (2014) · World Psychiatry · doi:10.1002/wps.20145 · Cited by 154
Drug targets for cognitive enhancement in neuropsychiatric disorders.
Wallace, T. L., Ballard, T. M., Pouzet, B., Riedel, W. J., & Wettstein, J. G. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.022 · Cited by 127
Renard, J., Szkudlarek, H. J., Kramar, C. P., Jobson, C. E. L., Moura, K., Rushlow, W. J., & Laviolette, S. R. (2017) · Scientific Reports · doi:10.1038/s41598-017-11645-8 · Cited by 125
Innovative solutions to novel drug development in mental health
Insel, T. R., Voon, V., Nye, J. S., Brown, V. J., Altevogt, B. M., Bullmore, E. T., Goodwin, G. M., Howard, R. J., Kupfer, D. J., Malloch, G., et al. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.022 · Cited by 124
Visual Surround Suppression in Schizophrenia
Tibber, M. S., Anderson, E. J., Bobin, T., Antonova, E., Seabright, A., Wright, B., Carlin, P., Shergill, S. S., & Dakin, S. C. (2013) · Frontiers in Psychology · doi:10.3389/fpsyg.2013.00088 · Cited by 116
Gamma oscillation deficits and the onset and early progression of schizophrenia
Woo, T.-U. W., Spencer, K., & McCarley, R. W. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673221003747609 · Cited by 96
Antidepressant-like properties of α2-containing GABAA receptors
Vollenweider, I., Smith, K. S., Keist, R., & Rudolph, U. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.10.009 · Cited by 96
Perisomatic inhibition and cortical circuit dysfunction in schizophrenia
Lewis, D. A., Fish, K. N., Arion, D., & Gonzalez-Burgos, G. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.05.013 · Cited by 87
Self-citationRole of GABAA receptors in cognition
Möhler, H. (2009) · Biochemical Society Transactions · doi:10.1042/bst0371328 · Cited by 79
Ranlund, S., Adams, R. A., Díez, Á., Constante, M., Dutt, A., Hall, M., Maestro Carbayo, A., McDonald, C., Petrella, S., Schulze, K., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23035 · Cited by 77
“, 2014], cognitive dysfunction and the development of symptoms of psychosis [Ahn et al., 2011; Lewis et al., 2008; Spencer et al., 2004].”
BackgroundKikuchi, M., Hashimoto, T., Nagasawa, T., Hirosawa, T., Minabe, Y., Yoshimura, M., Strik, W., Dierks, T., & Koenig, T. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.06.003 · Cited by 74
“…prefrontal cognitive dysfunctions in schizophrenia were ameliorated by treatment with MK-0777 (a benzodiazepine-like agent with selective activity at GABAA receptors containing α2 or α3 subunits) and these improvements were associated with increased frontal gamma activity (Lewis et al., 2008).”
BackgroundMethodThe Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis
Taylor, S. F., Grove, T. B., Ellingrod, V. L., & Tso, I. F. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz046 · Cited by 67
Renard, J., Rushlow, W. J., & Laviolette, S. R. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00281 · Cited by 62
“For example, chronic treatment with a GABA-A α2/3-selective agonist in patients with schizophrenia, attenuates attentional and working memory deficits and normalize the associated abnormalities in gamma oscillatory activities (153).”
BackgroundTek, C., Palmese, L. B., Krystal, A. D., Srihari, V. H., DeGeorge, P. C., Reutenauer, E. L., & Guloksuz, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.002 · Cited by 59
“Eszopiclone is an agonist on GABA-A receptors; and specific GABA-A modulators have previously been shown to improve working memory in schizophrenia (Lewis et al., 2008).”
BackgroundAtack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52
Broader visual orientation tuning in patients with schizophrenia
Rokem, A., Yoon, J. H., Ooms, R. E., Maddock, R. J., Minzenberg, M. J., & Silver, M. A. (2011) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2011.00127 · Cited by 50
Reversal of Ketamine-Induced Working Memory Impairments by the GABAAα2/3 Agonist TPA023
Castner, S. A., Arriza, J. L., Roberts, J. C., Mrzljak, L., Christian, E. P., & Williams, G. V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.001 · Cited by 37
Atack, J. R., Wong, D. F., Fryer, T. D., Ryan, C., Sanabria, S., Zhou, Y., Dannals, R. F., Eng, W.-S., Gibson, R. E., Burns, H. D., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157909 · Cited by 36
Koychev, I., Barkus, E., Ettinger, U., Killcross, S., Roiser, J. P., Wilkinson, L., & Deakin, B. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111414450 · Cited by 24
Wierońska, J. M., & Pilc, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.010 · Cited by 23
Metadata
- Authors
- Lewis, D. A., Cho, R. Y., Carter, C. S., Eklund, K., Forster, S., Kelly, M. A., & Montrose, D.
- Venue
- American Journal of Psychiatry
- Published
- 2008-12
- Volume
- 165
- Issue
- 12
- Pages
- 1585-1593
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2106257034
- Cited by
- 292
- References
- 43
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.